Santaris Raises $12M in Private Investment Round | GenomeWeb

Santaris Pharma this week announced that it has raised $12 million through the sale of convertible bonds to existing private investors and members of the company's management.

Santaris said that proceeds from the financing would primarily be used to fund the continued development of its microRNA-targeting hepatitis C drug miravirsen, which is under phase II development, as well as its pipeline of other locked nucleic acid-based therapeutic candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.